Four Patients Treated in Phase 2 Trial Testing Topical Gene Therapy, KB103, for Wound Healing
All four patients with dystrophic epidermolysis bullosa (DEB) enrolled in a Phase 2 study testing the safety and efficacy of Krystal Biotech’s topical gene therapy candidate KB103 have received the treatment. Results are expected to be known by mid-year. The protein type 7 collagen (Col7) binds the two top layers…